Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence. Read More
Can HYMPAVZI change hemophilia care for patients with inhibitors? Pfizer’s Phase 3 results signal a new standard
Pfizer’s HYMPAVZI showed 93% fewer bleeds in hemophilia patients with inhibitors. Explore how this subcutaneous treatment could redefine care standards. Read More
Can immunotherapy finally replace chemo in bladder cancer? Keytruda–Padcev combo shows the way
Explore how Merck’s Keytruda and Padcev combo is redefining bladder cancer treatment without chemo. Survival gains, sector impact, and what’s next in focus. Read More
XOMA Royalty completes LAVA Therapeutics acquisition in push to strengthen bispecific antibody pipeline
Find out how XOMA Royalty’s acquisition of LAVA Therapeutics strengthens its oncology royalty portfolio and expands its partnered bispecific antibody programs. Read More
Metsera picked Pfizer over Novo Nordisk — here’s what swung the $10bn deal
Pfizer secures obesity biotech Metsera for $10 billion after regulatory pushback sidelines Novo Nordisk. Find out what this means for pharma M&A now. Read More
Why Pfizer’s $10bn Metsera deal could reshape the obesity drug market in 2026 and beyond
Pfizer beats Novo Nordisk in $10B Metsera buyout, reshaping obesity drug competition. Find out what this means for the pharma M&A and GLP-1 space. Read More
Pfizer thought it secured Metsera—then Novo Nordisk crashed the party with a bigger bid
Novo Nordisk just challenged Pfizer’s Metsera deal with a $9B rival bid. Find out how this could reshape the weight-loss drug landscape in 2025. Read More
Pfizer data reveal sustained survival with BRAFTOVI + MEKTOVI in rare lung cancer subtype
Find out how Pfizer’s BRAFTOVI + MEKTOVI combination is redefining survival for BRAF V600E-mutant lung cancer and what it means for Pfizer’s oncology strategy. Read More
How AstraZeneca’s $4.5bn Virginia investment aligns with Trump-era tariffs and U.S. supply chain policy
Find out how AstraZeneca’s $4.5 billion Virginia API plant could reshape global pharma supply chains and investor sentiment in 2025. Read More
Valneva slashes 2025 outlook after FDA suspends Ixchiq license, shaking investor confidence
Valneva slashes 2025 outlook after FDA suspends Ixchiq license—discover how the biotech aims to rebuild confidence and cash flow stability. Read More